4.7 Article

Cardiac Rehabilitation for Patients With Heart Failure

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 77, 期 11, 页码 1454-1469

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2021.01.030

关键词

activity; cardiac rehabilitation; exercise; exercise training; functional status; heart failure

资金

  1. Abbott Vascular
  2. Roche Diagnostics
  3. Merck
  4. Bayer
  5. National Institute on Aging
  6. National Institutes of Health Common Fund [R01AG060499, R01AG058883, P30AG024827, UO1AR071130]
  7. National Institutes of Health
  8. AstraZeneca
  9. Sensible Medical
  10. Respicardia
  11. LivaNova

向作者/读者索取更多资源

Cardiac rehabilitation, which includes exercise training, risk factor modification, and outcomes assessment, is safe and beneficial for patients with HF. Despite its effectiveness and cost-efficiency, it is currently underused and should be prioritized as part of standard care for HF patients.
Cardiac rehabilitation is defined as a multidisciplinary program that includes exercise training, cardiac risk factor modification, psychosocial assessment, and outcomes assessment. Exercise training and other components of cardiac rehabilitation (CR) are safe and beneficial and result in significant improvements in quality of life, functional capacity, exercise performance, and heart failure (HF)-related hospitalizations in patients with HF. Despite outcome benefits, cost-effectiveness, and strong practice guideline recommendations, CR remains underused. Clinicians, health care leaders, and payers should prioritize incorporating CR as part of the standard of care for patients with HF. Published by Elsevier on behalf of the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据